10 years ago, during the deadliest Ebola virus disease outbreak that killed more than 11,000 people in West Africa, there were no antiviral treatments or vaccines available to respond to or prevent an outbreak. Ten years on, there are now two approved Ebola treatments and two approved Ebola vaccines.
However, the treatments are not readily accessible in places where they’d likely be needed in a future outbreak. In addition, they remain under the exclusive control of just two US pharmaceutical corporations, Regeneron and Ridgeback, and almost all the treatments currently available worldwide are kept in a national security and biodefense stockpile held for use by the United States.

These slides are a general explainer for a lay audience highlighting the lessons learned from the research and development of Ebola treatments, and what needs to be done for them to become accessible for all.

Link to design template : https://www.canva.com/design/DAF-7rovzSI/qlGV6Y8ns1yP1IXDQPWMNQ/view?utm_content=DAF-7rovzSI&utm_campaign=designshare&utm_medium=link&utm_source=publishsharelink&mode=preview